Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Research & Development (2016 - 2025)

Historic Research & Development for China Pharma Holdings (CPHI) over the last 13 years, with Q3 2025 value amounting to $40321.0.

  • China Pharma Holdings' Research & Development fell 5397.67% to $40321.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $91407.0, marking a year-over-year decrease of 7878.93%. This contributed to the annual value of $283942.0 for FY2024, which is 1826.97% up from last year.
  • China Pharma Holdings' Research & Development amounted to $40321.0 in Q3 2025, which was down 5397.67% from $20952.0 recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Research & Development peaked at $190086.0 during Q1 2021, and registered a low of $547.0 during Q4 2024.
  • Its 5-year average for Research & Development is $58931.8, with a median of $40321.0 in 2025.
  • Within the past 5 years, the most significant YoY rise in China Pharma Holdings' Research & Development was 59202.0% (2024), while the steepest drop was 9962.93% (2024).
  • Quarter analysis of 5 years shows China Pharma Holdings' Research & Development stood at $54048.0 in 2021, then plummeted by 48.2% to $27999.0 in 2022, then soared by 426.99% to $147552.0 in 2023, then tumbled by 99.63% to $547.0 in 2024, then surged by 7271.3% to $40321.0 in 2025.
  • Its Research & Development was $40321.0 in Q3 2025, compared to $20952.0 in Q2 2025 and $29587.0 in Q1 2025.